These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12415821)

  • 1. Histone deacetylation inhibitors.
    Ardizzoni A; Loprevite M
    Suppl Tumori; 2002; 1(4):S52-4. PubMed ID: 12415821
    [No Abstract]   [Full Text] [Related]  

  • 2. Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.
    Neal JW; Sequist LV
    J Clin Oncol; 2012 Jun; 30(18):2280-2. PubMed ID: 22508823
    [No Abstract]   [Full Text] [Related]  

  • 3. The rational basis of using novel targeted biological agents in non-small cell lung cancer.
    Ciardiello F
    Suppl Tumori; 2002; 1(4):S31-3. PubMed ID: 12415813
    [No Abstract]   [Full Text] [Related]  

  • 4. Tyrosine kinase signal transduction inhibitors. Clinical trials.
    Scagliotti GV
    Suppl Tumori; 2002; 1(4):S34-6. PubMed ID: 12415814
    [No Abstract]   [Full Text] [Related]  

  • 5. Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer.
    Mukhopadhyay NK; Weisberg E; Gilchrist D; Bueno R; Sugarbaker DJ; Jaklitsch MT
    Ann Thorac Surg; 2006 Mar; 81(3):1034-42. PubMed ID: 16488717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the epidermal growth factor receptor a new strategy in cancer treatment.
    Gianni L; Grasselli G
    Suppl Tumori; 2002; 1(4):S60-1. PubMed ID: 12415824
    [No Abstract]   [Full Text] [Related]  

  • 7. Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC.
    Van Zandwijk N; Baas P
    Suppl Tumori; 2002; 1(4):S37-8. PubMed ID: 12415815
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiangiogenic agents.
    Stani SC; Capaccetti B; Bonginelli P; Sarmiento R; De Sio L; Fanelli M; Gasparini G
    Suppl Tumori; 2002; 1(4):S39-43. PubMed ID: 12415816
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeted biological treatments in NSCLC. Farnesyl transferase inhibitors.
    Marangolo M
    Suppl Tumori; 2002; 1(4):S49. PubMed ID: 12415819
    [No Abstract]   [Full Text] [Related]  

  • 10. Histone deacetylase inhibitors in non-small-cell lung cancer.
    Witta S
    J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S404-6. PubMed ID: 23160335
    [No Abstract]   [Full Text] [Related]  

  • 11. [ZD1839].
    Nakagawa K
    Nihon Rinsho; 2002 May; 60 Suppl 5():378-83. PubMed ID: 12101693
    [No Abstract]   [Full Text] [Related]  

  • 12. Developing targeted therapies for lung cancer.
    Gandara DR
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):648-9, 690. PubMed ID: 16258461
    [No Abstract]   [Full Text] [Related]  

  • 13. The potential of histone deacetylase inhibitors in lung cancer.
    Aparicio A
    Clin Lung Cancer; 2006 Mar; 7(5):309-12. PubMed ID: 16640801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.
    Piekarz RL; Sackett DL; Bates SE
    Cancer J; 2007; 13(1):30-9. PubMed ID: 17464244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The new drugs and biologics as sensitizers in the treatment of non-small cell lung cancer.
    Turrisi AT
    Suppl Tumori; 2002; 1(4):S55-7. PubMed ID: 12415822
    [No Abstract]   [Full Text] [Related]  

  • 16. Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect?
    Damaskos C; Tomos I; Garmpis N; Karakatsani A; Dimitroulis D; Garmpi A; Spartalis E; Kampolis CF; Tsagkari E; Loukeri AA; Margonis GA; Spartalis M; Andreatos N; Schizas D; Kokkineli S; Antoniou EA; Nonni A; Tsourouflis G; Markatos K; Kontzoglou K; Kostakis A; Tomos P
    Anticancer Res; 2018 Jan; 38(1):37-43. PubMed ID: 29277754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors in cancer therapy.
    Fouladi M
    Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting epigenetic abnormalities with histone deacetylase inhibitors.
    Conley BA; Wright JJ; Kummar S
    Cancer; 2006 Aug; 107(4):832-40. PubMed ID: 16826577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Targeted therapies for lung cancer].
    Tamura K
    Rinsho Ketsueki; 2008 Aug; 49(8):616-21. PubMed ID: 18800610
    [No Abstract]   [Full Text] [Related]  

  • 20. Current treatment of non-small cell lung cancer.
    Tonato M
    Suppl Tumori; 2002; 1(4):S7-8. PubMed ID: 12415804
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.